Image

Global Short Bowel Syndrome Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Short Bowel Syndrome Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Short Bowel Syndrome Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 1.44 USD Billion
Diagram Market Size (Forecast Year) USD 4.40 USD Billion
Diagram CAGR %

Major Markets Players

  • Takeda Pharmaceutical Company Limited
  • Johnsons & Johnsons Services
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries
  • Sanofi

Global Short Bowel Syndrome Drugs Market, By Drug Class (Glucagon-like Peptide, Anti-Diarrheal, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, Others), Route of Administration (OralParenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Short Bowel Syndrome Drugs Market

Short Bowel Syndrome Drugs Market Analysis and Size

Short bowel syndrome is related with small intestine surgeries. It is characteristically acquired over the individual’s lifespan and genetically occurs only in few cases.  Currently, there is no cure for short bowel syndrome and the treatment is targeted toward its symptoms. In some cases, short bowel syndrome can be life-threatening, but the disease can be managed through effective medication. In addition to this, government bodies are directly taking part in boosting the confidence of local manufacturers through various initiatives.

Data Bridge Market Research analyses a growth rate in the global short bowel syndrome drugs market in the forecast period 2022-2029. The expected CAGR of global short bowel syndrome drugs market is tend to be around 15% in the mentioned forecast period. The market was valued at USD 1.44 billion in 2021, and it would grow upto USD 4.40 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Short Bowel Syndrome Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Glucagon-like Peptide, Anti-Diarrheal, Histamine Blockers, Proton Pump Inhibitors, Growth Hormone, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Takeda Pharmaceutical Company Limited (Japan), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), and Hikma Pharmaceuticals PLC (U.K.)

Market Opportunities

  • High Cost of Parenteral Nutrition
  • Increasing Demand for Retail Pharmacies

Market Definition

Short bowel syndrome drugs is a type of rare gastrointestinal disease wherein a patient either lose a large amount of intestine or are born with inadequate amount of intestine as well as dysfunctional intestine that finally results in the malnutrition because it cannot effectively absorb the nutrients from the food.  

Global Short Bowel Syndrome Drugs Market Dynamics

Drivers

  • Increased Demand of Intravenous Supplementation of Fluids

There is a rising demand for intravenous supplementation of fluids for maintaining the normal hydration and urinary flow for patients who are suffering from this syndrome. Several key manufacturers in the short bowel syndrome market are making efforts to meet this demand, since these patients suffer from complications such as hyponatremia, dehydration, and chronic renal failure. Hypomagnesemia is caused by malabsorption of magnesium because of the loss of the distal ileum, several manufacturers are producing magnesium supplements to help the patients achieve adequate hydration.

  • Prevalence of Short Bowel Syndrome

Incidence of short bowel syndrome has increased across the globe in the past few years. The increasing patients number on total parenteral nutrition has led to the increase in the market growth. The occurrence of short bowel syndrome is projected to be about four people per million, and the occurrence is about three people per million. Although the exact prevalence of the disease is not clear, it is expected based on the number of people on parenteral nutrition.

Opportunities

  • High Cost of Parenteral Nutrition

The huge cost of parenteral nutrition increases the demand for short bowel syndrome drugs, that have clearly shown the ability to reduce patients' dependence on parenteral nutrition during clinical trials. For instance, apraglutide has the advantage to enable patients to reduce the burden from parenteral support by growing intestinal absorption of fluids, calories, and nutrients. Apraglutide has completed phase 2 trial and is currently being assessed in a pivotal phase 3 clinical trial.

  • Increasing Demand for Retail Pharmacies

The rise in the number of short bowel syndrome drugs delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients opt for retail pharmacies for buying drugs, as these are easily available.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with these agents could curb the growth of the global short bowel syndrome drugs market over a forecast period.

  • High Cost

The cost of treatment of these type of syndromes  is significantly high, that makes the treatment unaffordable, especially for low-income groups. For instance, in May 2019, the U.S. FDA approved extending the indication of Gattex (teduglutide) for injection to paediatric patients with an age group of 1 year and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug that is used to treat adults having short bowel syndrome (SBS). Also, it has been noticed that Gattex is quite expensive, with treatment costing over US$ 295,000 a year.

This global short bowel syndrome drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global short bowel syndrome drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide. It is a next-generation, long-acting GLP-2 analog that is being developed for rare gastrointestinal diseases and used for the prevention of acute graft-versus-host disease (aGVHD).
  • In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. FDA had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912). LAPS GLP-2 Analog is a new biopharmaceutical that has been developed for short-bowel syndrome with the company's platform technology, Labscovery. The disorder occurs in approximately 24.5 out of 100,000 newborns and majorly affects the growth of children and adolescents, with a survival rate under 50%.

Global Short Bowel Syndrome Drugs Market Scope

The global short bowel syndrome drugs market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Glucagon-like Peptide
  • Anti-Diarrheal
  • Histamine Blockers
  • Proton Pump Inhibitors
  • Growth Hormone
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Short Bowel Syndrome Drugs Market Regional Analysis/Insights

The global short bowel syndrome drugs market is analyzed and market size insights and trends are provided by drug class, drug, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global short bowel syndrome drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global short bowel syndrome drugs market throughout the forecasted period due to the high prevalence of short bowel syndrome and increase in research and development activity.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Short Bowel Syndrome Drugs Market Share Analysis

The global short bowel syndrome drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global short bowel syndrome drugs market.

Key players operating in the global short bowel syndrome drugs market include:

  • Takeda Pharmaceutical Company Limited (Japan)
  • Johnsons & Johnsons Services Inc (U.S.)
  • Boehringer Ingelheim International GmbH (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Sanofi (France)
  • GSK Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Alvogen (U.S)
  • Hikma Pharmaceuticals PLC (U.K.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Short Bowel Syndrome Drugs Market is projected to grow at a CAGR of 15.0% during the forecast period by 2029.
The future market value of the Short Bowel Syndrome Drugs Market is expected to reach USD 4.40 billion by 2029.
The major players in the Short Bowel Syndrome Drugs Market are Takeda Pharmaceutical Company Limited (Japan), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), etc.
The countries covered in the Short Bowel Syndrome Drugs Market are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials